ReviewInfection2022
Antibiotics in the pipeline: a literature review (2017-2020).
Review in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Natural Product-Based Strategies for Combating Antimicrobial Resistance in ESKAPE Pathogens.Current microbiology · 2026Review
- Article
- Clinical application and safety observation of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia.BMC infectious diseases · 2026Article
- The COMBINE pneumonia model: a multicenter study to standardize a mouse pneumonia model withMicrobiology spectrum · 2026Article
- Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming.PLoS pathogens · 2026Article
- Mapping the Proteomes of Bacteriophages E215 and LUZ19 Using Liquid Chromatography Tandem Mass Spectrometry.Advances in experimental medicine and biology · 2026Article
- Molecular Epidemiology of Carbapenem-ResistantMicroorganisms · 2025Article
- The Current Landscape of Antibiotic Use and Antimicrobial Resistance in Japan: Focusing on Common Infections Including Uncomplicated Urinary Tract Infection and Gonorrhea.Antibiotics (Basel, Switzerland) · 2025Review
- Sustainable, Targeted, and Cost-Effective Laccase-Based Bioremediation Technologies for Antibiotic Residues in the Ecosystem: A Comprehensive Review.Biomolecules · 2025Review
- Impact of pulmonary infection and antibiotic use on recurrent myocardial infarction in patients with myocardial infarction.Scientific reports · 2025Article
- Rational design of synthetic antimicrobial peptides based on the Escherichia coli ShoB toxin.Scientific reports · 2025Article
- Bioactive Fraction of Streptomyces thinghirensis MSA1 Effectively Inhibits Biofilm Forming Clinically Significant AMR Pathogens.Current microbiology · 2025Article
- Antibacterial carbon dots.Materials today. Bio · 2025Review
- ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro.Nature microbiology · 2025Article
- Synthesis and Antibacterial Activity of New 6″-Modified Tobramycin Derivatives.Antibiotics (Basel, Switzerland) · 2024Article
- The Comparative Characterization of a HypervirulentInternational journal of molecular sciences · 2024Article
- An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia byHealth science reports · 2024Article
- Cannabinoids in Integumentary Wound Care: A Systematic Review of Emerging Preclinical and Clinical Evidence.Pharmaceutics · 2024Review
- Non-Canonical Aspects of Antibiotics and Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Combining machine learning with high-content imaging to infer ciprofloxacin susceptibility in isolates of Salmonella Typhimurium.Nature communications · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntimicrobial resistance (AMR) is an emerging global threat. It increases mortality and morbidity and strains healthcare systems. Health care professionals can counter the rising AMR by promoting antibiotic stewardship and facilitating new drug development. Even with the economic and scientific challenges, it is reassuring that new agents continue to be developed.
methodsThis review addresses new antibiotics in the pipeline. We conducted a review of the literature including Medline, Clinicaltrials.org, and relevant pharmaceutical companies for approved and in pipeline antibiotics in phase 3 or new drug application (NDA).
resultsWe found a number of new antibiotics and reviewed their current development status, mode of action, spectra of activity, and indications for which they have been approved. The included studies from phase 3 clinical trials were mainly utilized for the treatment of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and pneumonia acquired in the healthcare settings. The number of these agents is limited against high priority organisms. The identified antibiotics were based mainly on previously known molecules or pre-existing antimicrobial agents.
conclusionThere are a limited number of antibiotics against high priority organisms such as multi-drug-resistant Pseudomonas aeruginosa, and carbapenem-resistant Enterobacteriaceae. New antimicrobial agents directed against the top priority organisms as classified by the World Health Organization are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.